Monthly Archives: October 2013

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Tagged , , , , , | Leave a comment

CEOs Sound Out on Health Reform: Stop Swinging from the Fence

At last week’s  4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.  The centerpiece of the day was a panel on  US health reform – focused on rollout of the  Affordable Care Act — featuring […]
Posted in Events, leadership, People, R&D, Regulatory | Tagged , , , , , , , , , , , , | Leave a comment

Pharma's Transparency Troubles

Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler It seems like open season on the pharmaceutical industry. Academics and consumer activists charge pharma companies with hiding clinical trial information on medical product safety, fueling […]
Posted in Europe, FDA, Guest Blog, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

Europe's Mooted 'Passport for Physicians': Implications for Patients

Europe moved one step closer to a passport for physicians in early October. The European Parliament gave its backing to creating a virtual professional qualifications card that will allow doctors, pharmacists, and other professionals to practice in another EU country. The system also envisages an alert system, so that health professionals barred in one country […]
Posted in Europe, Global, Guest Blog, Strategy | Tagged , , , , , | Leave a comment

CPhI Industry Report Outlines Trends Driving Pharma Innovation

CPhI Worldwide and CPhI Pharma Evolution, part of UBM Live’s Pharmaceutical Portfolio, today released Part II of the CPhI annual industry report, in which expert industry panel members share their views on trends that will drive growth and innovation across the pharmaceutical industry over the coming years and beyond. The pharmaceutical industry is shifting away […]
Posted in Guest Blog, Strategy | Tagged , , , , | Leave a comment
  • Categories

  • Meta